Recently, Celgene Corporation (Nasdaq: CELG ) has settled a legal dispute with Elan Corporation (NYSE: ELN ) regarding cancer injection Abraxane. Abraxane became a part of Celgene's portfolio in October 2010 with Celgene's acquisition of Abraxis BioScience Inc. Legal action against Abraxis BioScience was initiated by Elan in 2006.